Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review

Ayman Grada1 | Steven R. Feldman2 | Nicola Luigi Bragazzi3 | Giovanni Damiani4,5,6

1R&D and Medical Affairs, Almirall (US), Exton, PA
2Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC
3Department of Mathematics and Statistics, Laboratory for Industrial and Applied Mathematics (LIAM), York University, Toronto, Ontario, Canada
4Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
5Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy
6Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy

Correspondence
Giovanni Damiani, Clinical Dermatology, IRCCS Galeazzi Orthopaedic Institute, Via Riccardo Galeazzi, 4, 20161, Milan, Italy. Email: dr.giovanni.damiani@gmail.com

Abstract
Patients' perspectives on actinic keratosis treatments may have an impact on treatment adherence and, therefore, therapeutic outcomes. We performed a systematic review to assess patients' perspectives of topical, field-directed treatments for actinic keratoses. A literature search was conducted, and 14 studies were identified encompassing 4433 patients. Only four studies were focused on face and/or scalp, which are the locations that typically impact patients' quality of life. Four studies were clinical trials. One study utilized a validated patient-reported outcomes (PRO) instrument specifically developed for actinic keratosis. In general, treatment adherence and patient satisfaction were better with shorter-duration treatment regimens such as ingenol mebutate gel. Imiquimod improved quality of life in one study but not in another. No data was available on topical piroxicam. The findings underscore the need for effective and well-tolerated, short-duration topical treatment for actinic keratosis.

KEYWORDS
actinic keratosis, adherence, compliance, patient-reported outcomes, topical, safety, systematic review, tolerability

1 | INTRODUCTION

Actinic keratoses (AKs), also known as solar or senile keratoses, are chronic, recurrent cutaneous lesions resulting from the proliferation of atypical epidermal keratinocytes due to prolonged intermittent sun exposure and may progress to cutaneous squamous cell carcinoma. AK is one of the most common reasons for dermatology office visits, especially among the elderly.1 AK treatments can also be quite distressing to many patients due to impact on daily activities such as work and social engagements, especially for lesions in the face and scalp.

Currently, there are two major categories of AK treatments: lesion-directed and field-directed therapies.1 The latter include photodynamic therapy (PDT) and topical treatments such as 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, and piroxicam; they are typically used for treating areas with multiple AKs or clinical evidence of field cancerization. Fluorouracil acts by inhibiting thymidylate synthetase limiting DNA synthesis and causing cell death.2,4 Imiquimod is an immune response modifier which activates Toll-like receptor 7 (TLR-7), causing the release of cytokines by epidermal and dermal dendritic cells; imiquimod also modulates the response of natural killer cells (NKs) and B-lymphocytes. Ingenol mebutate disrupts plasma membranes and mitochondria and induces neutrophil-mediated cellular cytotoxicity.2,4 Both piroxicam and diclofenac inhibit cyclooxygenase enzymes (COX-1 and COX-2). The use of ingenol mebutate for the field treatment of actinic keratosis has been associated with increased risk of nonmelanoma skin cancer (NMSC) and has been withdrawn from the market.

Understanding patients’ perspective regarding topical AK treatments may help optimize patients’ adherence and clinical outcomes.5-26 A patient-reported outcome (PRO) is a report coming
directly from the patient, concerning her health status and experience with a particular treatment. Patient-reported outcome measures (PROMs) are instruments to assess PROs from a quantitative standpoint. To better understand patients’ perspectives of AK treatment, we performed a systematic review of PROs of topical field-directed AK treatment.

2 MATERIALS AND METHODS

2.1 Systematic review development and protocol

The present systematic review was devised based on the “Preferred Reporting Items for Systematic Reviews and Meta-analyses” (PRISMA) guidelines and the Cochrane recommendations for developing a systematic review of patient-reported outcome measure (PROM) studies. The systematic review was further based on a protocol, developed according to the “Preferred Reporting Items for Systematic Reviews and Meta-analyses—Protocol” (PRISMA-P). The protocol has been submitted to the “International Prospective Register of Systematic Reviews” (PROSPERO) for registration and is also available upon request to the Corresponding Author.

2.2 Inclusion and exclusion criteria

Inclusion criteria were the following: P (patients suffering from AK), I (intervention, any topical field treatment for AK), C (all the articles reporting topical therapy for AK, independently from the comparison with another drug or placebo— including imiquimod, ingenol mebutate, diclofenac, piroxicam, 5FU), O (outcomes, PROs/PROMs), and S (study design, any study design). Expert opinions, comments/commentaries, letters to editor, editorials, case reports, case series, and reviews were excluded.

2.3 Search strategy

Search string consisted of relevant keywords (such as “actinic keratosis” and synonyms—actinic or senile keratosis—and safety, tolerability, quality of life, patient satisfaction, patient-reported outcome—PRO—or patient-reported outcome measure—PROM—patient perspective, patient preference or patient perception), connected by means of appropriate Boolean operators. PubMed/MEDLINE was queried from 1 January 2010 to 6 December 2020, utilizing the “Best Algorithm” option; medical subject headings (MeSH) terms and truncated words/wild-card option were used when appropriate (Table 1).

Extensive cross-referencing and scanning of list of references of each potentially eligible study were performed, in order to minimize the risk of missing relevant investigations. Already available reviews were assessed for ensuring an adequate coverage but were not included in the present systematic review. No time or language filters were applied. The literature search was performed independently by two authors (Nicola Luigi Bragazzi, an expert in research methodology, and Giovanni Damiani, a dermatologist) and disagreements were solved by discussion until consensus was reached.

2.4 Data abstraction

The following data and information were extracted: surname of the first author, study year, country in which the study was performed, sample size, mean age, male percentage, skin phototype percentages, previous history of skin cancer and AK, previous treatment received, PROs/PROMs investigated and major findings and conclusions of the study. Two authors independently (Nicola Luigi Bragazzi and Giovanni Damiani) performed the data abstraction and any disagreement was solved through discussion until consensus was reached. Data abstraction was first pilot-tested in a small sub-set of studies randomly generated from sample of the included studies.
2.5 | Literature synthesis

Data extracted was synthesized and displayed using tables, charts, and a narrative overview.

3 | RESULTS

3.1 | Literature search

The initial literature search yielded a pool of 594 items (Figure 1). After screening title and/or abstract, 579 were removed. Three studies were excluded with reason (Table 2). Finally, 14 studies were included in the present systematic review (Table 3).

3.2 | Characteristics of the included studies

Included studies were published between 2010 and 2020. Only four studies were clinical trials,\textsuperscript{10,23-25} Investigations were designed prevalently as national studies (10/14)\textsuperscript{6,10,12,15-17,22,23,26} and carried out in North America,\textsuperscript{10,15} Europe,\textsuperscript{6,16,17,22,26} South America,\textsuperscript{6,23} and Australia.\textsuperscript{12} Brazil was the only represented South American country,\textsuperscript{6,23} and no data were present to represent Asian and African countries. Sample size ranged from 1522 to 11368 patients, totaling a sample of 4433 patients for all included studies.\textsuperscript{6,8,10,12,13,15-17,19,22-26} The examined population were prevalently Caucasian males with face and scalp AK.

AK lesions involving any part of the body were assessed by most of the studies,\textsuperscript{8,10,13,16,17,23,25,26} whereas four studies focused on only face and/or scalp treatment.\textsuperscript{6,22,24} 5% to 57.9% of patients had a previous history of skin cancer, while 19.3% to 90.3% had been previously treated for AK.\textsuperscript{6,8,10,12,13,15-17,19,22-26} The majority of the patients belonged to Fitzpatrick's skin phototypes I and II.\textsuperscript{6,8,10,12,13,15-17,19,22-26}
## TABLE 3  Included study list with their characteristics

| First author       | Study year | Country                | Sample size | Age                | Male    | Skin phototypes          | Ethnicity               | History of skin cancer | Previous history of AK and treatment | Areas treated                          | Dimension of areas treated |
|-------------------|------------|------------------------|-------------|--------------------|---------|--------------------------|-------------------------|------------------------|-------------------------------------|-------------------------------|--------------------------|
| Augustin et al.    | 2015       | USA, Australia         | 1005 patients | 65.1 y (34-89 y)   | 74.70%  | Majority with I and II phototypes | White/Caucasian (100%) | From 4.4% to 53.5% | Small percentage had been treated with imiquimod and topical fluorouracil (19.3% to 24.1%) | Face (43.8%), scalp (10.6%), arm (29.0%), back of hand (10.9%), chest (2.5%), leg (1.9%), back (0.7%), shoulder (0.6%) | NR                       |
| Berman et al.      | 2017       | USA                    | 188 patients | From 64.0 y to 67.7 | From 62.9% to 98.4% (depending on the group – based on the anatomical location) | I (from 7.9% to 19.4%), II (from 39.7% to 58.1%), III (from 19.4% to 47.6%), IV (from 3.2% to 4.8%) | From 98.4% to 100.0% (depending on the group – based on the anatomical location) | From 3.3% to 38.1% for NMSC | From 76.2% to 90.3% | Face/chest (33.5%), scalp (33.5%) and trunk or extremities (33.0%) | NR                        |
| Emilio et al.      | 2016       | USA                    | 28 patients, totaling 83 AK lesions | ≥65 y | 100% | NR | White/Caucasian (100%) | NR | NR | Face | 25 cm² contiguous |
| Gameiro et al.     | 2019       | Brazil                 | 37 patients, totaling 68 AK lesions | 68.81 ± 7.72 y (49-85 y) | 51.35% | II (64.6%) and III (24.30%) | Caucasian (97.30%) | 48.65% | 54.05% | Nasal (33.82%), forehead (37.94%), malar (23.53%), scalp (14.70%) | 91.18% (larger than 5 per 25 cm² skin area) |
| Hanke et al.       | 2020       | USA, Canada, Australia | 729 patients | Ingenol mebutate group = 68.0 y (38-91) and Vehicle group = 69.0 y (45-91) | 73.40% | I (18.9%), II (49.2), III (27.4%), IV (4.3%), V (0.1%) | Not Hispanic or Latino (99.6%), Hispanic or Latino (0.4%) | NR | NR | Face, Scalp and chest | Full scalp, full face, chest (250 cm²) |
| Jubert-Estève et al.| 2015       | Spain                  | 19 patients | 76.2 ± 7.7 y | 89.50% | II (63.2%), III (21.1%), IV (15.8%) | NR | 57.9% for NMSC | 68.4% | Face (47.2%), scalp (42.1%), dorsum of hands (5.3%), forarm (5.3%) | 97.0 ± 81.1 cm² |
| Neri et al.        | 2019       | Italy                  | 1136 patients | From 71.7 y to 73.8 y | 73.20% | II (15.1%) | NR | NR | Arm (4.1%), trunk (4.7-9.2%), face (23-42.5%), scalp (47.3-60.3%) | NR |
| First author      | Study year | Country              | Sample size | Age          | Male | Skin phototypes | Ethnicity       | History of skin cancer | Previous history of AK and treatment | Areas treated | Dimension of areas treated |
|-------------------|------------|----------------------|-------------|--------------|------|-----------------|-----------------|-----------------------|--------------------------------------|--------------|--------------------------|
| Norrlid et al.    | 2018       | Denmark, Sweden      | 446 patients | 69.9 ± 9.0 y | 56%  | I (17%), II (68%), III (14%), and IV (1%) | NR              | SCC (7%), BCC (35%), melanoma (5%) | 75% (treated in 74% of patients) | Face (70%), scalp (22%), trunk (4%), extremities (4%) | 23.8 ± 34.6 cm² |
| Platsidaki et al. | 2020       | Greece               | 440 patients | 73.5 y (NR SD) | 65.90% | I (7.3%), II (44.8%), III (39.3%), IV (8.0%), V (0.7%) | NR              | NR | 35.9% had previous AK treatment; prevalently with imiquimod, surgical/curettage and cry/liquid nitrogen | Unknown in 27.1%, and prevalently on face (36.7%) and scalp (16.1%) | NR |
| Schlaak et al.    | 2010       | Germany              | 15 patients  | >70          | 94%  | NR              | NR              | NR | NR | NR | Face/Head | NR |
| Segatto et al.    | 2013       | Brazil               | 31 patients  | 74.4 ± 8.31 (Diclofenac sodium) and 71.54 ± 8.60 (Fluorouracil) | 46.40% | I (39.2%), II (50.0%), III (10.7%) | NR              | NR | 15 (48.4) had a previous skin cancer not specified in the manuscript | NR | Face, Scalp and Back of the hands | NR |
| Stockfleth et al. | 2017       | Germany and UK       | 166 patients | 72.2 ± 7.1 y | 87.70% | I (8.6%), II (80.4%), III (10.4%), IV (0.6%) | White / Caucasian (100.0%) | NR | NR | NR | Scalp (45.2%), Face/forehead (54.8%) | 25 cm² |
| Strydom et al.    | 2018       | New Zealand          | 75 patients out of an initial list of 100 patients | 66 y (29-88 y) | NR | NR | NR | NR | NR | Face | 100 cm² |
| Waalboer-Spuij et al. | 2015 | Netherlands          | 118 patients | 67 ± 10 y | 58%  | NR | NR | Melanoma (5%), BCC (36%), SCC (11%), other skin malignancies | 67% | Face/head/neck (66%), scalp (20%), torso (14%), arms (16%), legs (3%) | NR |
| First author          | Study design                                      | AK location                          | Treatment administered                                | Adherence to treatment | PROs                                                                 |
|-----------------------|--------------------------------------------------|--------------------------------------|------------------------------------------------------|------------------------|----------------------------------------------------------------------|
| Augustin et al.        | Post-hoc analyses from four phase-III, multi-center, randomized, double-blind, vehicle-controlled trials | Face, scalp, trunk and extremities | 0.015% ingenol mebutate for 3 days or 0.05% for 2 days | From 98.2% to 98.7%    | Significant, positive associations between TSQM score and degree of clearance were identified for patients in Significant association between Skinindex-16 score and clearance for patients in the face/scalp group for change in symptoms. Emotions, and over all Skinindex-16 score from baseline. |
| Berman et al.          | Phase II, multicenter, open-label trial           | Any part of the body (face, chest, scalp, trunk or extremities), with no lesions (from 74.2% to 85.7%), 1-2 lesions (from 11.1% to 11.3%), | Ingenol disoxate gel applied once daily for 3 consecutive days (0.018% for face and chest, 0.037% for scalp and 0.1% for trunk or extremities) | 97% (from 95% to 98%, depending on the specific area) | Treatment satisfaction score ranging from 66.7/100 to 91.3/100. Based on the specific area, global satisfaction scores were 73.9/100, 79.7/100, 66.7/100 for the face/chest, scalp, and trunk/extremities groups, respectively |
| Emilio et al.          | Prospective pilot study                           | Face                                 | 0.015% ingenol mebutate gel applied once daily for 3 consecutive days | NR                     | Mean overall scores improved from 24.5% at baseline to 15.5% as assessed on day 60. More in detail, treatment impacted on quality of life in a large and positive way for patients with mild and moderate LSR (Cohen's d 2.1 and 1.8, respectively) and had, instead, little impact in patients with severe LSR (Cohen's d 0.2) |
| Gameiro et al.         | Retrospective, descriptive, observational         | Face and scalp                       | 0.015% ingenol mebutate gel for 3 days               | 100%                   | Perception of the treatment: great (75.68%)                             |
|                       |                                                   |                                      |                                                      |                        | Discomfort: reasonable (40.54%), no discomfort (13.1%)                |
|                       |                                                   |                                      |                                                      |                        | Adverse reactions: erythema and local pruritus (16%) particularly disturbing |
|                       |                                                   |                                      |                                                      |                        | Self-esteem: improved in 97.30% cases                                  |
|                       |                                                   |                                      |                                                      |                        | Overall score: 9.4 (7-10)                                             |
| Hanke et al.           | Phase 3, randomized, parallel-group, double-blind, vehicle-controlled trial | Face, scalp, chest                   | Ingenol mebutate 0.027% gel                          | 4 patients drop-out    | Patients who received ingenol mebutate were more satisfied.           |
| Jubert-Esteve et al.   | Prospective, non randomized pilot study           | Any part of the body                 | Imiquimod 5% and ingenol mebutate                    | 0 drop-out             | After treatment with ingenol mebutate, significant improvement was observed in the Skinindex-29 subscales relating to symptom severity, the patients' emotional state, and in the overall score. Imiquimod 5% and ingenol mebutate achieved higher median scores for effectiveness and global satisfaction than any other previous treatments (as measured by TSQM 1.4) |
| Neri et al.            | Observational, multicentre, longitudinal, cohort study | Any part of the body                 | Ingenol mebutate, diclofenac, hyaluronic acid, Imiquimod 5% | 46% avoided application within 2 h before bedtime, 14% washed the treated area ever than 6 h post application. Patients undergoing long term treatment skip more than 20% of the applications in 5.2% of ingenol treated patients and in 74% of patients treated with different topical drugs | Treatment satisfaction was higher for ingenol mebutate. Clarity in the communication between the physician and the patient was associated with a higher adherence and treatment satisfaction |
| First author | Study design | AK location | Treatment administered | Adherence to treatment | PROs | Main findings |
|--------------|--------------|-------------|-------------------------|------------------------|------|---------------|
| Norrlid et al. | Observational, multicentre, real-life study | Any part of the body, with 9.4 ± 8.2 lesions on average | diclofenac gel, imiquimod 3.75% or 5% or ingenol mebutate 150 μg/g or 500 μg/g | Treatment adherence was generally high, but higher for ingenol mebutate compared to both diclofenac (p < .001) and imiquimod (p = .007), possibly due to shorter treatment duration | TSQM-9, MMAS, EQ-5D-5L, EQ-VAS, AKQoL | Treatment satisfaction was higher for ingenol mebutate compared to patients treated with diclofenac |
| Platsidaki et al. | Noninterventional multicenter study | Face (61.6%), Scalp (32.5%) and others (5.9%) | Face and scalp: 150 mcg/g ingenol mebutate gel during 3 consecutive days; Other locations: 500 mcg/g ingenol mebutate gel for 2 days | 100% | EQ-5D questionnaire, EQ VAS and TSQM-9 | Patients reported high satisfaction, especially in case of complete AK clearance. |
| Schlaak et al. | Single center, prospective study | Face/Head | Solution of 5 mg fluorouracil (0.5%) and 100 mg salicylic acid (10%) 3 times per day for 4 weeks | 1 patient drop-out due to side effects | Treatment satisfaction VAS | Patients satisfaction was “good” |
| Segatto et al. | Randomized, parallel-group clinical trial | Face, Scalp and Back of the hands | 3% diclofenac sodium with 2.5% hyaluronic acid gel twice daily for 12 weeks vs. 5% 5-Fluorouracil cream twice daily for 4 weeks | 3 patients drop-out in the 5FU group. | Treatment satisfaction VAS | In relation to satisfaction regarding the adverse effects, the group treated with DFS showed higher satisfaction compared to the group treated with 5-FU, with 93.3% and 38.4% of highly satisfied patients, respectively. Regarding the patients’ evaluation, most were highly satisfied with the improvement of the lesions in both groups, with no statistically significant difference. When considering the degree of improvement, more than half of the patients (54%) in the group treated with 5-FU considered themselves to be fully healed, compared to 20% in the group treated with DFS. |
| Stockfleth et al. | Phase III, multicenter, randomized, double-blind, vehicle-controlled study | Scalp and face/forehead | 5-FU 0.5% plus salicylic acid 10% | 2 patients drop-out | TSQM and DLQI | Treatment satisfaction scores were higher in treated patients when compared to vehicle. No statistically significant differences were observed between the study arms for the TSQM convenience and side effect domain scores. |
| Strydom et al. | Single-center, prospective, questionnaire-based study | Face | 0.015% ingenol mebutate applied once daily for 3 consecutive days, over areas up to 100 cm² | NR | Ad hoc, nonvalidated 11-item questionnaire | Treatment satisfaction was rather high (86–89%). Pretreatment education was appreciated by all patients. 58% patients experienced moderate-to-severe pain. 51%, 41% and 9% found their appearance, pain and anxiety particularly distressing, respectively. 31% would have discontinued the treatment in case of self-application, with 82% preferring in-clinic application |
| Waalboer-Spuij et al | Multicenter open-label study | Any part of the body, with 1 lesion (25%), 2–4 lesions (13%), 5–9 lesions (29%), ≥10 lesions (31%) | 5% imiquimod cream once daily, 3 days per week, for 4 weeks | 6-7% of patients decided to discontinue the therapy | Skindex-17, TSQM, SCI adapted to AK | Imiquimod had no impact on health-related quality of life. Overall treatment satisfaction was less than 60/100 |

Abbreviation: NR - Not reported.
3.3 Utilization of PRO instruments

The included studies reported several PRO instruments that could be categorized into AK-specific and non-specific instruments. Only one study utilized a validated AK-specific instrument, the Actinic Keratosis Quality of Life questionnaire (AKQoL), which assesses quality of life but not patients’ satisfaction with treatment.27

Non AK-specific validated instruments reported include Treatment Satisfaction Questionnaire for Medication (TSQM),8,10,13,16,17,19,24,26 Skindex-16,15,19,25 Skindex-17,17 Skin Cancer Index (SCI),17 Patient Health Questionnaire-4 (PHQ-4),9 EuroQol 5-level EQ-5D version (EQ-5D-5L),13,26 EuroQol Visual Analogue Scale (EQ-VAS),13,26 and Dermatology Life Quality Index (DLQI).24

Four studies utilized ad-hoc, non-validated questionnaires.6,10,12,23 Five studies utilized only one PRO (ad-hoc questionnaire6,12,23 vs validated questionnaire11,15), while 11 studies used more than one PRO instrument (only validated questionnaires13,17,19,24,26 vs validated and not validated questionnaires8,10). One study used a validated questionnaire, the Morisky Medication Adherence Scale (MMAS), to quantify patients’ adherence.13

3.4 Patient-reported outcomes

Ten studies evaluated a single AK topical drug (imiquimod 5%,17 ingenol mebutate,6,12,15,19,25,26 ingenol disoxate,10 5-FU22,24) finding acceptable overall satisfaction. Four studies compared different topical treatments (diclofenac vs 5-FU,23 diclofenac vs imiquimod vs ingenol mebutate,8,12 ingenol mebutate vs imiquimod 5%).19

Ingenol mebutate and ingenol disoxate appeared to be well-tolerated by patients, with rather high treatment satisfaction scores and improved quality of life.6,8,10,12,15,19,25,26 In a small pilot study (n=19), both imiquimod 5% and ingenol mebutate achieved higher median scores for effectiveness and global satisfaction than any other previous treatments. However, ingenol mebutate achieved higher median score on convenience.16 Ingenol mebutate was superior to diclofenac in terms of satisfaction and treatment adherence.8,13 Diclofenac caused fewer adverse events (erythema, edema, crusts and itching) than 5-FU.23

When compared with other available pharmacological options, ingenol mebutate, a topical treatment with simpler and shorter-duration regimen, appeared to be superior to the comparators from the patients’ perspective.

Adherence to the treatment was generally very high for shorter-duration treatments, with few patients reporting treatment discontinuation due to side effects.5,8,10,12,13,15,17,19,22,26

No data was identified for piroxicam.

4 DISCUSSION

Actinic keratoses are chronic, recurring lesions and represent a substantial disease burden due to their high prevalence and associated risk of frank malignancy. Furthermore, AKs are quite distressing to many patients not only as a cosmetic liability, but also treatment-related local skin reactions occurring on habitually exposed body locations, particularly the face and bald scalp, with significant impact on daily living activities such as work and social life.1

This systematic review explored PROs/PROMs regarding topical field-directed treatment for AK. Investigating patients’ perspective is crucial when different treatment options exist, especially when facial and scalp lesions are detrimental in terms of perceived quality of life. Most included studies employed a small sample size, with few being clinical trials and only one utilized a validated instrument specifically developed for AK. Development and use of psychometrically sound and validated instruments may advance the field.

One important limiting factor for some AK topical treatments is poor tolerability due to local skin reaction. A prospective, open-label, multicenter study by Stough et al included 277 patients treated with once daily application of 5-FU 0.5% cream for up to 4 weeks. In an interim analysis of the face and scalp findings, severe local skin reactions (LSRs) developed in nearly 20% of patients.28 Severe LSRs such redness, pain, erosions and ulcerations can have an impact on patients’ social activities and hence poor adherence to therapy.29

Imiquimod showed efficacy17 but lower tolerability and patient’s satisfaction than ingenol mebutate.8,13,30 Furthermore, imiquimod can trigger latent, unpredictable inflammatory dermatoses, particularly on the scalp31 and also may trigger distant inflammatory mucosal reactions.30

In addition to tolerability, prolonged treatment duration is a significant factor contributing to nonadherence and nonpersistance to topical treatments. In a community-based, cross-sectional study, patient-applied topical therapies that required less frequent application and have shorter treatment duration were associated with better adherence rates.32 Our study results shows that patient satisfaction corresponds with shorter duration of topical treatment.

Involving patients and empowering them, implementing patient-centered care and taking into account patients’ preferences and perspectives could enhance and improve their health status, paving the way also for personalized management options. Within this conceptual framework, patient education is fundamental, especially for multiple AK lesions. Pre-treatment education is appreciated by patients and results in a high treatment satisfaction scores (in the range 86-89%).12

New venues in the field could include the study of the feasibility of exploiting educational videos or the new information and communication technologies (ICTs) to improve patients’ satisfaction and adherence to the treatment.14

On the other hand, despite its transparency, rigor, methodological strengths, and reproducibility, the present study is not without limitations. The major shortcomings are given by the small studies included and by mining only PubMed/Central. The high heterogeneity among studies did not enable to carry out a meta-analysis.

5 CONCLUSIONS

Actinic keratoses are precursors for invasive cutaneous squamous cell carcinoma. Different treatment options exist for actinic keratoses.
Topical therapies with simpler and shorter-treatment regimen appeared to achieve high patient satisfaction, better adherence and improve overall quality of life. Incorporating patients’ perspective in clinical trials may be helpful. Well-designed studies utilizing validated PRO instruments should help define patients’ preferences.

ACKNOWLEDGMENTS
We thank Prof. Thomas McCormick for the support and suggestions. Open access support provided by Almirall.

CONFLICT OF INTEREST
Ayman Grada, MD, MS is an employee of Almirall LLC. Steve Feldman, MD, PhD received research, speaking and/or consulting support from Galderma, GSK/Stiefel, Almirall, Alvotech, Leo Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Lilly, Menlo, Helsinn, Arena, Forte, Merck, Novartis, Regeneron, Sanofi, Novan, Quirent, National Biotechnological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He consults for others through Guidepoint Global, Gerson Lehrman and other consulting organizations. He is founder and majority owner of www.DrScore.com. He is also a founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment.

AUTHOR CONTRIBUTIONS
CRediT (Contributor Roles Taxonomy): Conceptualization: Ayman Grada, Steven R. Feldman, Nicola Luigi Bragazzi, and Giovanni Damiani; Methodology: Giovanni Damiani and Nicola Luigi Bragazzi; Software: Nicola Luigi Bragazzi; Validation: Ayman Grada, Nicola Luigi Bragazzi, and Giovanni Damiani; Formal analysis: Nicola Luigi Bragazzi; Investigation: Ayman Grada, Steven R. Feldman, Nicola Luigi Bragazzi, and Giovanni Damiani; Resources: Ayman Grada; Data curation: Nicola Luigi Bragazzi and Giovanni Damiani; Writing: Ayman Grada, Nicola Luigi Bragazzi, Giovanni Damiani; Revision & Editing: Ayman Grada, Steven R. Feldman, Nicola Luigi Bragazzi, and Giovanni Damiani; Visualization: Giovanni Damiani and Nicola Luigi Bragazzi; Supervision: Giovanni Damiani, Ayman Grada; Project Administration: Nicola Luigi Bragazzi, and Giovanni Damiani. All authors read and approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID
Ayman Grada https://orcid.org/0000-0002-5321-0584
Giovanni Damiani https://orcid.org/0000-0002-2390-6505

REFERENCES
1. Gilchrest BA. Actinic keratoses: reconciling the biology of field carcinogenesis with treatment paradigms. J Invest Dermatol. 2020; S0022-202X(20)32068-6. [online ahead of print].
2. Yaldiz M. Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. Medicine (Baltimore). 2019;98(28):e16465.
3. Dziunycz PJ, Schuller E, Hoffbauer GF. Prevalence of actinic keratosis in patients attending general practitioners in Switzerland. Dermatology. 2018;234(5–6):214-219.
4. Velter C. Épidémiologie des kératoses actiniques: epidemiology of actinic keratosis. Ann Dermatol Venereal. 2019;146(Suppl 2):IIS3-IIS9.
5. Johnston BC, Patrick DL, Devji T, et al. Chapter 18: Patient-reported outcomes. In: Higgins JPT, Thomas J, Chandler J, et al., (eds.). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley; 2019: 479-492.
6. Gameiro L, Tovo LFR, Sanches Júnior JA, Aprahamian I. Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients’ perspectives. An Bras Dermatol. 2019;94(3):313-319.
7. Salido-Vallejo R, González-Velasco M, Guilabert M, García EL, Mira JJ. The perception of care received by patients with actinic keratosis. J Healthc Qual Res. 2018;33(6):360-369.
8. Nerli L, Peris K, Longo C, et al. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol. 2019;33(1):93-107.
9. Kopasker D, Kwiatkowski A, Matin RN, et al. Patient preferences for topical treatment of actinic keratoses: a discrete-choice experiment. Br J Dermatol. 2019;180(4):902-909.
10. Berman B, Tyring S, Nahm WK, Østerdal ML, Petersen AH, Siegel DM. Three-day field treatment with ingenol disoxate (LEO 43204) for actinic keratosis: cosmetic outcomes and patient satisfaction from a phase II trial. J Clin Aesthet Dermatol. 2017;10(11):26-32.
11. Philipp-Dormston WG, Müller K, Novak B, et al. Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression. J Eur Acad Dermatol Venereol. 2018;32(7):1138-1146.
12. Strydom F. In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: results of a questionnaire. Australas J Dermatol. 2018;59(3):237-239.
13. Norrild H, Norlin JM, Holmstrup H, et al. Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients. J Dermatol Treat. 2018;29(1):68-73.
14. Agbai OK, Davari P, Johnson J, Armstrong A, Fazeli N. Effect of a pre-treatment educational video in improving patient satisfaction with 5-fluorouracil treatment for actinic keratoses: a randomized controlled trial. Dermatol Ther (Heidelb). 2016;6(4):675-683.
15. Emilio J, Schwartz M, Feldman E, et al. Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study. Clin Cosmet Investig Dermatol. 2016;9:89-93.
16. Jubert-Esteve E, del Pozo-Hernando LJ, Izquierdo-Herce N, et al. Quality of life and side effects in patients with actinic keratoses treated with ingenol mebutate: a pilot study. Actas Dermosifiliogr. 2015;106(8):644-650.
17. Waalboer-Spuij R, Holterhues C, van Hattem S, et al. Patient perception of imiquimod treatment for actinic keratoses and superficial basal cell carcinoma in 202 patients. Dermatology. 2015;231(1):56-62.
18. Longo I, Serra-Guillén C. Quality of life, behaviour and attitudes towards actinic keratosis in Spain: the PIQA study. Actas Dermosifiliogr. 2018;109(4):331-339.
19. Augustin M, Tu JH, Knudsen KM, Erntoft S, Larsson T, Hanke CW. Ingenol mebutate gel for actinic keratoses: the link between quality of life, treatment satisfaction and clinical outcomes. J Am Acad Dermatol. 2015;72(5):816-821.
20. Khanna R, Bakshi A, Amir Y, Goldberg G. Patient satisfaction and reported outcomes on the management of actinic keratosis. Clin Cosmet Investig Dermatol. 2017;10:179-184.
21. Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. *J Eur Acad Dermatol Venereol*. 2017;31(Suppl 2):17-20.

22. Schlaak M, Simon JC. Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid: pilot study. *J Dtsch Dermatol Ges*. 2010;8(3):174-178.

23. Segatto MM, Dornelles SI, Silveira VB, Frantz Gde O. Comparative study of actinic keratoses treatment with 3% diclofenac sodium and 5% 5-fluorouracil. *An Bras Dermatol*. 2013;88(5):732-738.

24. Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and safety of 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. *Dermatol Ther (Heidelb)*. 2017;7(1):81-96.

25. Hanke CW, Albrecht L, Skov T, Larsson T, Østerged ML, Spelman L. Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm² on the chest: a phase 3 randomized controlled trial. *J Am Acad Dermatol*. 2020;82(3):642-650.

26. Platsidaki E, Kostopoulos N, Panagakis P, Cheliotis G, Antoniou C, Kontochristopoulos G. The use of ingenol mebutate to treat actinic keratosis in standard clinical practice: a prospective phase IV multicenter observational cohort study. *Int J Dermatol*. 2020;59(6):690-697.

27. Esmann S, Vinding GR, Christensen KB, Jemec GB. Assessing the influence of actinic keratosis on patients’ quality of life: the AKQoL questionnaire. *Br J Dermatol*. 2013;168(2):277-283.

28. Stough D, Bucko AD, Vamvakias G, Rafał ES, Davis SA. Fluorouracil cream 0.5% for the treatment of actinic keratoses on the face and anterior scalp: interim results of an 18-month open-label study. *J Clin Aesthet Dermatol*. 2008;1(2):16-21.

29. Balcerz A, Rone Kupfere M, Čema I, Krůmíra A. Prevalence, discontinuation rate, and risk factors for severe local site reactions with topical field treatment options for actinic keratosis of the face and scalp. *Medicina*. 2019;55(4):92.

30. Hammerl V, Parlar B, Navarini A, Gantenbein L, Väth H, Mueller SM. Mucosal side effects in patients treated with topical imiquimod: a scoping review of the literature. *Dermatol Ther*. 2020;e14355. [online ahead of print].

31. Vaccaro M, Barbuzzo O, Guarneri B. Erosive pustular dermatosis of the scalp following treatment with topical Imiquimod for actinic keratosis. *Arch Dermatol*. 2009;145(11):1340-1341.

32. Shergill B, Zokale S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. *Patient Prefer Adherence*. 2014;8:35.